Immuneering Corporation Price, Forecast, Insider, Ratings, Fundamentals & Signals

- preclinical data presented at aacr demonstrate that combining imm-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either treatment alone - - patients are now on treatment in multiple arms of the ongoing phase 2a trial, including multiple patients with pancreatic cancer who are being treated with imm-1-104 in combination with chemotherapy in the first-line setting - - immuneering expects initial data from multiple imm-1-104 phase 2a arms in 2024 - cambridge, mass., april 09, 2024 (globe newswire) -- immuneering corporation (nasdaq: imrx), a clinical-stage oncology company seeking to develop and commercialize universal-ras/raf medicines for broad populations of cancer patients, today presented preclinical data at the american association for cancer research (aacr) annual meeting, which the company views as supportive of its ongoing phase 2a clinical trial of imm-1-104 in ras-mutated advanced or metastatic solid tumors.

Cambridge, mass., april 03, 2024 (globe newswire) -- immuneering corporation (nasdaq: imrx), a clinical-stage oncology company seeking to develop and commercialize universal-ras/raf medicines for broad populations of cancer patients, today announced that management will participate in the 23rd annual needham virtual healthcare conference, taking place april 8-11, 2024, to discuss the company's pipeline, platform, and business strategy.

- deep cyclic inhibitor of the mapk pathway demonstrated strong tumor growth inhibition in preclinical studies of raf or ras mutant tumors, both as monotherapy and in combination - - phase 1 portion of the phase 1/2a trial designed to evaluate the safety, tolerability, pharmacokinetics (pk), and pharmacodynamics (pd) of imm-6-415 and establish a candidate recommended phase 2 dose (rp2d) - -initial pk, pd and safety data expected in 2024 - cambridge, mass., march 27, 2024 (globe newswire) -- immuneering corporation (nasdaq: imrx), a clinical-stage oncology company seeking to develop and commercialize universal-ras/raf medicines for broad populations of cancer patients, today announced that the first patient has been dosed in its phase 1/2a trial of imm-6-415 to treat advanced solid tumors with raf or ras mutations.

- imm-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired ras alterations was observed in evaluable patients profiled for ctdna and treated with imm-1-104, supporting goal of universal-ras activity - - target lesion regression observed in over half of patients treated with imm-1-104 at 320mg or 240mg qd, with best individual lesion regression of -35.7% and best recist sum of longest diameters (sld) of -18.9%, both at 320mg - - candidate rp2d of 320 mg qd supported by tolerability, pk/pd, ctdna results & initial anti-tumor activity - - phase 2a portion of the study underway with three monotherapy and two combination arms in earlier lines of treatment, with initial data from multiple arms expected in 2024 - - immuneering will host an investor call today at 8:30 a...

Cambridge, mass., march 12, 2024 (globe newswire) -- immuneering corporation (nasdaq: imrx), a clinical-stage oncology company seeking to develop and commercialize universal-ras/raf medicines for broad populations of cancer patients, today announced the appointment of thomas j.

Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024.

Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California.

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in two February investor conferences to discuss the company's pipeline, platform and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will present preclinical data on IMM-1-104, its lead clinical-stage program, and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston.

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Chief Accounting Officer and Treasurer.

IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going to take time.

The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Jefferies Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.